Allison Dorval - Nov 29, 2024 Form 4 Insider Report for Verve Therapeutics, Inc. (VERV)

Role
Chief Financial Officer
Signature
/s/ Andrew Ashe, as Attorney-in-Fact for Allison Dorval
Stock symbol
VERV
Transactions as of
Nov 29, 2024
Transactions value $
-$3,130
Form type
4
Date filed
12/3/2024, 04:30 PM
Previous filing
Jun 21, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VERV Common Stock Options Exercise +1.88K +46.18% 5.94K Nov 29, 2024 Direct F1
transaction VERV Common Stock Sale -$3.13K -555 -9.35% $5.64 5.38K Dec 2, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VERV Restricted Stock Units Options Exercise $0 -1.88K -50% $0.00 1.88K Nov 29, 2024 Common Stock 1.88K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date,
F2 This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on December 9, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.
F3 On November 29, 2021, the reporting person was granted 7,500 RSUs pursuant to the Verve Therapeutics, Inc. 2021 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on November 29, 2022 and the remainder vesting in equal annual installments until November 29, 2025.